EN DE
STOCK COMPARISON

Celltrion Pharm vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Celltrion Pharm (068760) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Celltrion Pharm as the less overvalued of the two: Celltrion Pharm trades at KRW 44,200 versus a fair value of KRW 22,076 (-50%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
Celltrion Pharm
068760.KQ · KRW · Health Care
-50%
upside to fair value
overvalued
PriceKRW 44,200
Fair ValueKRW 22,076
Quality65/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Celltrion PharmJiangsu Hengrui Medicine Co
Valuation
P/E (TTM)43.6×
P/S (TTM)10.84×
P/B5.76×
EV/EBITDA33.0×
PEG0.93×
0.5%Dividend yield0.4%
KRW 200Dividend per share¥0.20
Profitability
9%Net margin25%
11%Operating margin32%
9%Return on equity15%
3%Return on assets9%
Growth
93%Revenue growth (YoY)13%
11.6%Avg. growth/yr (3Y)13.9%
18.1%Avg. growth/yr (5Y)2.5%
Balance & size
$1BMarket cap$52B
healthyGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 3 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Celltrion Pharmof which business quality 64 · market factors 23 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
42
63
Quality GrowthAre margins and returns improving?
68
41
CashflowEarnings quality: real cash, not paper profit
73
82
Fin. StrengthBalance sheet, leverage, solvency risk
68
100
InvestmentDisciplined investing over empire-building
72
27
Low VolatilityCalm price path (market factor)
50
78
MomentumPrice trend over the last 3–12 months (market factor)
9
35
52W MomentumDistance to the 52-week high (market factor)
15
29
Net IssuanceBuybacks instead of dilution
69
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Celltrion Pharm

DCF ModelsKRW 37,785
Earnings-BasedKRW 17,048
MultiplesKRW 18,433
Asset-BasedKRW 6,600
Growth DCFKRW 40,876
Economic ProfitKRW 15,550
Growth EarningsKRW 24,003

22 of 24 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Celltrion Pharm
Bear KRW 14,847Fair Value KRW 22,076Bull KRW 27,787
KRW 44,200 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Celltrion Pharm · Health Care

Quality score65 · Top 25%
Fair value upside-50% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Celltrion Pharm as the less overvalued of the two: Celltrion Pharm trades at KRW 44,200 versus a fair value of KRW 22,076 (-50%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.